Roth Capital set a $10.00 price target on Savara (NASDAQ:SVRA) in a research report released on Tuesday, TipRanks reports. The brokerage currently has a hold rating on the stock.

SVRA has been the subject of several other reports. Zacks Investment Research downgraded Savara from a hold rating to a sell rating in a research note on Friday, March 8th. BidaskClub downgraded Savara from a sell rating to a strong sell rating in a research note on Saturday, January 19th. ValuEngine upgraded Savara from a sell rating to a hold rating in a research note on Monday, April 1st. Finally, LADENBURG THALM/SH SH restated a buy rating on shares of Savara in a research note on Friday, May 10th. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Savara has an average rating of Buy and a consensus price target of $20.83.

NASDAQ:SVRA opened at $11.05 on Tuesday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 15.63 and a current ratio of 12.05. Savara has a 12 month low of $6.21 and a 12 month high of $14.06. The stock has a market capitalization of $398.43 million, a price-to-earnings ratio of -8.57 and a beta of 1.07.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.05. Equities research analysts anticipate that Savara will post -1.55 EPS for the current fiscal year.

In related news, insider Jaakko Taneli Jouhikainen sold 25,000 shares of Savara stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $9.03, for a total value of $225,750.00. Following the completion of the transaction, the insider now directly owns 184,754 shares in the company, valued at $1,668,328.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO David L. Lowrance sold 7,500 shares of Savara stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $10.79, for a total value of $80,925.00. Following the completion of the transaction, the chief financial officer now owns 3,800 shares of the company’s stock, valued at $41,002. The disclosure for this sale can be found here. Insiders have sold 50,261 shares of company stock valued at $466,674 over the last 90 days. Insiders own 6.50% of the company’s stock.

Large investors have recently bought and sold shares of the stock. FMR LLC acquired a new position in Savara in the fourth quarter valued at approximately $2,830,000. Vanguard Group Inc boosted its stake in Savara by 23.6% in the third quarter. Vanguard Group Inc now owns 1,246,240 shares of the company’s stock valued at $13,908,000 after acquiring an additional 238,358 shares during the period. Vanguard Group Inc. boosted its stake in Savara by 23.6% in the third quarter. Vanguard Group Inc. now owns 1,246,240 shares of the company’s stock valued at $13,908,000 after acquiring an additional 238,358 shares during the period. BlackRock Inc. boosted its stake in Savara by 8.2% in the third quarter. BlackRock Inc. now owns 2,170,294 shares of the company’s stock valued at $24,220,000 after acquiring an additional 164,056 shares during the period. Finally, Morgan Stanley boosted its stake in Savara by 224.1% in the third quarter. Morgan Stanley now owns 205,560 shares of the company’s stock valued at $2,294,000 after acquiring an additional 142,140 shares during the period. Institutional investors and hedge funds own 47.99% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

See Also: How to interpret a stock’s beta number

Analyst Recommendations for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.